See the DrugPatentWatch profile for Diroximel
What does the FDA label say diroximel fumarate is for?
Diroximel fumarate (brand name Vumerity) is an FDA-approved treatment for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease with relapses. [1]
What dose does the FDA label specify?
The FDA prescribing information includes a two-part dosing approach: a starter titration period followed by a maintenance dose. [1]
(See the “Dosage and Administration” section of the label for the exact titration schedule and tablet strengths.)
What are the main side effects listed on the FDA label?
The FDA label lists common adverse reactions associated with diroximel fumarate, with the most important safety topics including gastrointestinal symptoms and effects related to lymphocyte counts. [1]
What monitoring does the FDA label require?
The prescribing information recommends laboratory monitoring, including monitoring lymphocyte counts, and guidance on what to do if counts drop. [1]
Who should not take it, and what warnings are on the label?
The FDA label includes warnings and precautions related to infections risk and lymphopenia (low lymphocyte counts), as well as guidance on handling treatment interruptions or discontinuation in certain situations. [1]
Drug interactions and “can I take it with…” questions
The FDA label discusses considerations around other medications and how diroximel fumarate should be used with specific drug types, including effects on lab monitoring and infection risk. [1]
Where can I read the exact FDA label text?
You can view the official FDA prescribing information for Vumerity (diroximel fumarate) here:
- FDA label / prescribing information for Vumerity (diroximel fumarate) [1]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214665